Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 USD | -6.40% | -7.18% | -13.80% |
06/05 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
06/05 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.80% | 237M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024